Physician profile
James Hansel Merritt
NPI 1801850763
$2,940.66
in general payments reported to CMS, 2019-2025
8 companies · $809 in 2025
The $809 reported for 2025 was more than what 75% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $71.69 · 2021: $219 · 2022: $611 · 2023: $679 · 2024: $443 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,123.74 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $930.52 | 2021-2023 | Tepezza |
| Merz Pharmaceuticals, LLC | $512.30 | 2022-2025 | Xeomin |
| Merz North America, INC. | $157.32 | 2019-2020 | |
| Halozyme INC | $125.93 | 2023 | |
| Merck Sharp & Dohme LLC | $49.89 | 2022-2024 | Bridion |
| Katena Products, INC. (Dba Corza Medical) | $22.68 | 2019 | |
| Abbvie INC. | $18.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Merritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.